content_image/155016.jpg content_image/155018.jpg content_image/155019.jpg
With aspirations to contribute to patients’ lives, we aim to deliver Astellas products to as many patients as possible and achieve strong patient satisfac- tion. For this, we believe that it is crucial to launch a steady stream of new products and provide proper, high-quality information. We recently launched Suglat and XTANDI. To ensure that these new drugs are used appropriately, we will work to provide accurate information to a range of medical professionals, including doctors. 

Meanwhile, the Japanese government has begun implementing various measures to optimize medical expenditures. In addition, society is putting increasingly stronger demands on companies for compliance. 

We will respond accurately to these changes in the operating environment, as we strive to fulfill medical needs by delivering drugs with high added value to patients. 

## Sales of Major Products 

<img src='content_image/155016.jpg'>

## Launch of New Products (2013.4–2014.6) 

<img src='content_image/155018.jpg'>

*Invoiced price base 

<img src='content_image/155019.jpg'>

